Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) COO Sells $1,053,695.40 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 5,556 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The shares were sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Stock Down 0.1 %

Shares of NASDAQ:BGNE opened at $191.32 on Friday. The firm has a market capitalization of $18.54 billion, a PE ratio of -25.27 and a beta of 0.59. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. BeiGene, Ltd. has a 52-week low of $126.97 and a 52-week high of $213.83. The firm has a fifty day moving average of $171.86 and a 200 day moving average of $161.92.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The company’s revenue was up 56.1% on a year-over-year basis. During the same period in the prior year, the company earned ($3.64) EPS. As a group, research analysts anticipate that BeiGene, Ltd. will post -5.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BGNE. Bank of America decreased their target price on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. lifted their price objective on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $239.81.

Institutional Investors Weigh In On BeiGene

Hedge funds have recently made changes to their positions in the business. Capital International Investors grew its holdings in shares of BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after purchasing an additional 727,556 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in BeiGene by 6.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after buying an additional 117,905 shares during the period. Capital International Inc. CA grew its stake in shares of BeiGene by 6.0% during the first quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock valued at $134,240,000 after buying an additional 48,615 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of BeiGene in the second quarter worth about $54,412,000. Finally, First Trust Advisors LP bought a new stake in shares of BeiGene in the 4th quarter valued at about $39,632,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.